Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04688671 · ClinicalTrials.gov registry record · Phase 2

Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain

A Phase 2 study of Diabetic Peripheral Neuropathy and Diabetic Peripheral Neuropathic Pain, sponsored by Eliem Therapeutics (UK).

Completed
Registry status
Phase 2
Development phase
167
Enrollment target
20
Study locations

NCT04688671 is a Phase 2 study of Diabetic Peripheral Neuropathy and Diabetic Peripheral Neuropathic Pain that has completed, run by Eliem Therapeutics (UK). The registered enrollment target is 167 participants, above the 119-participant average among 17 other Diabetic Peripheral Neuropathy trials with a reported enrollment target (40% higher). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04688671, a Phase 2 study of Diabetic Peripheral Neuropathy and Diabetic Peripheral Neuropathic Pain, has completed, sponsored by Eliem Therapeutics (UK).

COMPLETED
Registry status
Phase 2
Development phase
167 participants
Enrollment target
20
Study locations

Study Summary

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy and Safety of ETX 018810 in Subjects with Diabetic Peripheral Neuropathic Pain.

Conditions Studied

Diabetic Peripheral Neuropathy Diabetic Peripheral Neuropathic Pain

Interventions

  • DRUG Placebo
  • DRUG ETX-018810

Study Locations (20)

California

  • Neuro-Pain Medical Cneter - Fresno
  • Encompass Clinical Research - Spring Valley
  • Diabetes Research Center - Tustin

Florida

  • Charter Research - Lady Lake
  • Cordova Research Institute - Miami
  • Coral Research Clinic Corp - Miami

New York

  • IMA Clinical Research - New York
  • Upstate Clinical Research Associates - Williamsville

Utah

  • Alpine Research Organization - Clinton
  • Jean Brown Research - Salt Lake City

Alabama

  • Delta Clinical Research - Mobile

Arizona

  • Arizona Research Center - Phoenix

Connecticut

  • Chase Medical Research LLC - Hamden

Georgia

  • Better Health Clinical Reseach - Newnan

Trial Details

FieldValue
Enrollment Target 167 participants
Start Date 2020-11-09
Est. Completion 2022-02-18
Phase Phase 2

Sponsor

Eliem Therapeutics (UK)

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04688671

The ClinicalTrials.gov registry entry for NCT04688671 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 167 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 119-participant average among 17 other Diabetic Peripheral Neuropathy trials with a reported enrollment target (40% higher). The listed sponsor is Eliem Therapeutics (UK), which has 2 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Diabetic Peripheral Neuropathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04688671 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, New York.

Frequently Asked Questions

What is clinical trial NCT04688671 about?

NCT04688671 is a clinical study titled "Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain". A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy and Safety of ETX 018810 in Subjects with Diabetic Peripheral Neuropathic Pain.

What is the current status of trial NCT04688671?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 167 participants. The study started on 2020-11-09. Estimated completion is 2022-02-18.

What conditions does trial NCT04688671 study?

This clinical trial studies the following conditions: Diabetic Peripheral Neuropathy, Diabetic Peripheral Neuropathic Pain.

What interventions are being tested in trial NCT04688671?

The interventions under investigation include: Placebo (DRUG), ETX-018810 (DRUG).

Who is sponsoring clinical trial NCT04688671?

This trial is sponsored by Eliem Therapeutics (UK), which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04688671 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetic Peripheral Neuropathy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diabetic Peripheral Neuropathy

All registered trials for this condition

Diabetic Peripheral Neuropathic Pain

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.